CD28 and neoplasm: In BsAb therapy, while one antibody activates the effector T cell receptors such as CD3 and CD28, the other antibody causes a tumor-associated antigen, such as AFP, GPC3, and EpCAM, to initiate tumor cytotoxicity [86].